The Private Equity fund of Gilde Healthcare, a specialist healthcare investor, has acquired EUROPIN, a leading international developer and manufacturer of customised pen cannulas and lancet needles for diabetic use.
The Private Equity fund of Gilde Healthcare, a specialist healthcare investor, has acquired EUROPIN, a leading international developer and manufacturer of customised pen cannulas and lancet needles for diabetic use.
The acquisition of EUROPIN represents a major step for Gilde Healthcare in forming a leading integrated contract manufacturer for tailor-made cannulas and cannula systems, following its initial investment in German medtech company Acti-Med, less than 12 months ago. The transaction marks the third acquisition in the DACH region by Gilde Healthcare Private Equity in the past 12 months.
By joining forces, EUROPIN and Acti-Med will be able to significantly expand their footprint – in terms of geography as well as breadth and depth of the product portfolio. The joint vision: further expand and internationalise the business through organic growth and acquisitions. Following the combination, the group will represent one of the largest contract manufacturers of raw cannulas and cannula systems in Europe.
Acti-Med was acquired by Gilde Healthcare in April 2021.
